Solvias Earns EcoVadis Medal, Spotlighting ESG as a Key Industry Metric

KAISERAUGST, Switzerland – March 23, 2026 – Solvias, a global provider of chemistry, manufacturing, and controls (CMC) analytics for the life sciences sector, has been awarded a Bronze Medal from EcoVadis, a leading business sustainability rating platform. The recognition places the Swiss-headquartered company in the top 35% of more than 100,000 companies assessed globally, highlighting its significant progress in integrating environmental, social, and governance (ESG) principles into its core operations.

This achievement is more than a corporate accolade; it serves as a key indicator of a much broader transformation within the pharmaceutical and biotech industries. As pressure mounts from regulators, investors, and consumers, robust ESG performance is rapidly shifting from a 'nice-to-have' to a non-negotiable requirement for suppliers and partners throughout the complex drug development supply chain.

A Deliberate Path to Sustainability Recognition

Solvias's Bronze Medal is the result of a structured and accelerated sustainability journey. The company formally launched its ESG initiative in 2024, establishing a framework designed to produce measurable improvements. This deliberate approach yielded its first external validation in 2025, when it received an EcoVadis 'Committed Badge,' marking the beginning of its formal benchmarking process.

The progression to a Bronze Medal in just one year reflects the successful implementation of several key initiatives. The company has undertaken a comprehensive calculation of its corporate carbon footprint across Scopes 1, 2, and 3—covering direct emissions, indirect emissions from energy use, and all other emissions from its value chain. This foundational step has enabled the establishment of clear sustainability targets, which are guided by a five-year ESG roadmap.

Beyond environmental metrics, the company has also focused on strengthening its governance, ethical business practices, and sustainable procurement standards, addressing the full spectrum of criteria evaluated by EcoVadis, which includes environment, labor and human rights, ethics, and sustainable sourcing.

"Earning the EcoVadis Bronze Medal reflects the meaningful progress our teams have made in embedding sustainability into our operations and business practices," said Archie Cullen, CEO of Solvias, in a statement. "This recognition underscores our commitment to continuous improvement as we support our partners in advancing life-changing therapies responsibly."

The New Currency of Partnership: ESG in Pharma's Supply Chain

The recognition of a specialized service provider like Solvias underscores a powerful trend: sustainability is becoming a critical currency in forming and maintaining business partnerships in the life sciences. Major pharmaceutical and biotech companies are increasingly being held accountable for the environmental and social impact of their entire value chain, particularly their vast Scope 3 emissions.

This accountability is driven by multiple forces. Stringent new regulations, such as the EU's Corporate Sustainability Reporting Directive (CSRD), mandate extensive disclosure and due diligence on supply chain impacts. Simultaneously, investors are using ESG ratings to assess long-term risk and resilience, favoring companies with responsible and transparent operations. As a result, pharmaceutical giants are cascading these expectations down to their network of suppliers.

Companies across the sector are now integrating ESG performance into their procurement decisions. Many now require key suppliers to report their sustainability data through platforms like EcoVadis and to demonstrate their own commitments to decarbonization. For a CMC analytics firm, which provides essential services from raw material testing to final drug product release, demonstrating a strong ESG profile is becoming a prerequisite for securing and retaining contracts with industry leaders.

From Bronze Medal to Competitive Edge

In a competitive market, the EcoVadis Bronze Medal provides Solvias with a tangible competitive advantage. It serves as third-party validation of the company's commitment to responsible practices, offering assurance to current and potential clients that they are partnering with a supplier that aligns with their own sustainability goals. This can be a key differentiator when clients are choosing between technically proficient service providers.

While some larger, diversified players in the contract research and manufacturing space, such as WuXi AppTec and Lonza, have achieved Gold and Silver ratings respectively, Solvias's rapid advancement is noteworthy. The leap from a 'Committed Badge' to a Bronze Medal in a single year demonstrates significant momentum and an agile approach to ESG integration, positioning the company as a serious and proactive player in the sustainability arena.

This external validation not only enhances brand reputation but also aids in attracting and retaining top talent, as employees increasingly seek to work for companies with a strong ethical and environmental purpose. By embedding sustainability into its strategic priorities, Solvias is positioning itself not merely as a compliant vendor but as a forward-thinking partner invested in the long-term health of the industry and the planet.

Charting a Science-Based Future

Solvias is not resting on its current achievements. The company has signaled its intention for further alignment with internationally recognized frameworks, most notably the Science Based Targets initiative (SBTi). The SBTi provides a globally accepted methodology for companies to set greenhouse gas emissions reduction targets that are consistent with the level of decarbonization required to meet the goals of the Paris Agreement.

Committing to the SBTi framework would represent a significant next step, moving Solvias from benchmarking its current performance to setting a clear, scientifically validated path for future emissions reduction. This move would align the company with a growing number of industry leaders who have already had their targets validated by the SBTi, reinforcing its commitment to credible climate action.

By pursuing science-based targets, Solvias is preparing for a future where such commitments are standard practice. This forward-looking strategy ensures the company remains a relevant and valued partner, capable of supporting innovation in drug development while actively contributing to a more sustainable and resilient global healthcare supply chain.